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Abstract
Brachyspira pilosicoli is the etiologic agent of human and animal intestinal spirochetosis and is rarely
implicated as a cause of bacteremia. Here, we describe the case of a B. pilosicoli spirochetemia in a
53-year-old male patient suffering from cardiogenic shock. This fastidious bacterium was isolated
from blood, likely after translocation from the intestinal tract. Blood cultures were positive after 5
days of incubation (one day after the patient's death), highlighting the problem of the recovery of
such type of fastidious bacterium. Identification was achieved by molecular methods (16S rRNA
sequencing). A review of the English literature found only 8 cases of bacteremia caused by B.
pilosicoli, mostly in immunocompromised or critically ill patients. Finally, difficulties in rapid and
accurate diagnosis of B. pilosicoli bloodstream infections, in vitro antimicrobial susceptibility of
human clinical isolates, and therapeutic options are discussed.
Introduction
The genus Brachyspira, first described in 1982, belongs to
the order of the Spirochaetales (like Treponema) and
includes seven species to date: B. aalborgi, B. alvinipulli, B.
hyodysenteriae, B. innocens, B. intermedia, B. murdochii, and
B. pilosicoli http://www.bacterio.cict.fr/. Morphologically,
they are coiled Gram-negative bacilli (2 to 11 μm long; 0.2
to 0.5 μm in diameter) and are motile due to the presence
of flagella (8 to 30). These anaerobic intestinal spirochetes
colonize the large intestine of humans and many animal
species, and several species may cause diarrhea and other
gastrointestinal diseases in these hosts [1]. Although
Brachyspira (formerly Serpulina) pilosicoli is the etiologic
agent of porcine intestinal spirochetosis [2], B. pilosicoli
and B. alborgi are both described in humans and are con-
sidered as agents of human intestinal spirochetosis (HIS)
[3,4]. In addition, B. pilosicoli was also isolated from
patients with bacteremia, termed spirochetemia [5-7]. In
this report, we describe a case of spirochetemia due to B.
pilosicoli in a peculiar clinical context (cardiogenic shock)
and review the literature.
Case report
A 53-year-old man, obese and smoker, was admitted to
the cardiology unit of our hospital for shock associated
with a third-degree atrioventricular block. Upon admis-
sion, five sets of peripheral blood cultures were systemat-
ically drawn; however, antibiotics were not initiated
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because the patient was afebrile. In the cardiology unit, he
had two episodes of ventricular fibrillation treated by
external cardioversion. Coronarography was performed
and showed an occlusion of the right main coronary
artery that disappeared spontaneously whereas the left
main coronary artery was normal. Ventriculography was
normal and aortography revealed the absence of aortic
dissection. Due to persisting cardiogenic shock, the
patient was then transferred to the medical intensive care
unit on the same day where he received inotropic drugs.
Because of leukocytosis (white blood cell count of 16,000
cells/mm3) and hypothermia (body temperature at
35.3°C), an antibiotic treatment with cefotaxime (3 g
daily) was started. A transoesophageal echocardiography
revealed right atrial and ventricular massive dilatation and
an acute right ventricular dysfunction. A diagnosis of car-
diogenic shock due to transient occlusion of the right
main coronary artery was made. In the unit, his evolution
was rapidly unfavourable with the occurrence of multiple
and repeated episodes of ventricular fibrillation. The
patient died four days later in a context of multiple organ
failure associated with persistent cardiogenic shock and
right ventricular failure.
The day after of the patient's death (i.e. five days of incu-
bation), four out of five BacT/Alert® blood culture anaero-
bic bottles (bioMérieux, Marcy l'Etoile, France), yielded a
Gram-negative spiral-shaped bacterium, suggesting a spi-
rochete. After three days, the isolate was subcultured on
5% horse blood-containing agar plates under anaerobic
conditions at 37°C and the growth appeared as a thin film
with weak β-hemolysis. Phenotypically, all biochemical
tests except hippurate were negative using the API 20 ANA
and ID 32 ANA strips (bioMérieux). In addition, the iso-
late yielded a positive reaction for oxidase test and nega-
tive reactions for catalase and indole production tests.
Accurate identification of the clinical isolate was achieved
by 16S rRNA sequence analysis, as previously described
[8]. The 16S rRNA nucleotide sequence of the clinical iso-
late was then compared to deposited sequences available
from GenBank using the BLAST program. The sequence of
the clinical isolate was 100% identical with those of B.
pilosicoli  ATCC 51139 and P43/6/78 strains (GenBank
accession no. AY155458 and U14927, respectively).
Disk diffusion susceptibility testing was performed on
Mueller-Hinton agar supplemented with 5% defibrinated
horse blood according to the recommendations of the
Antibiogram Committee of the French Society for Micro-
biology http://www.sfm.asso.fr/publi/general.php?pa=1.
The strain was fully resistant to penicillin, amoxicillin,
ticarcillin and piperacillin by producing a β-lactamase
(cefinase test positive). It was also resistant to erythromy-
cin, spiramycin, rifampin, vancomycin and colistin, and
susceptible to amoxicillin/clavulanate, piperacillin/tazo-
bactam, cefoxitin, cefotaxime, imipenem, clindamycin,
pristinamycin, tetracyclin, chloramphenicol and metroni-
dazole.
Discussion
In this report, we describe a case of B. pilosicoli blood-
stream infection in a context of cardiogenic shock. To the
best of our knowledge, only a few cases of bacteremia
caused by this species have been reported in the literature.
Both B. aalborgi and B. pilosicoli are implicated as causal
agents of HIS, an infestation by spirochetal microorgan-
isms on the surface of the large intestinal mucosa first
described in 1967 [9]. The two species are zoonotic since
they have been isolated from the feces of non-human pri-
mates or other animals, such as dogs and birds [1]. Little
is known about the transmission of these spirochetes to
humans but it seems likely to occur by fecal-oral route,
e.g. after exposure to colonized/infected human or ani-
mals, their feces, or contaminated water [1]. The incidence
of B. aalborgii and B. pilosicoli infections in humans is
poorly investigated, but the use of species-specific PCR
assays should allow the prompt and accurate detection of
the spirochetes in clinical samples [4]. Prevalence of IS
varied considerably across geography and immune condi-
tions. Indeed, the prevalence of B. pilosicoli in rectal biop-
sies is reported to be 2–7% in Western countries, 11–34%
in less developed countries, and up to 54% in homosexual
men and HIV-infected patients [3,4,10,11]. It is notewor-
thy that intestinal colonization with B. pilosicoli appears
high (prevalence > 30%) in specific populations, such as
Australian Aboriginal children, Gulf Arabs, and villagers
in Papua New Guinea [4,12,13]. In certain conditions,
particularly immunosuppression, B. pilosicoli may translo-
cate from the large intestine to blood (causing spiroche-
temia) since the adherence of the spirochete to the colonic
epithelium is likely increased in these situations. Never-
theless, only 8 cases of B. pilosicoli bacteremia have been
previously described, including 6 cases from France in
patients older than 50-years and having a severe underly-
ing disease that led to death in four cases [5] (Table 1).
Two other cases have been reported, the first from the
United States in a Californian HIV-infected patient with a
Kaposi's sarcoma [6], and the second from Greece in an
immunocompromised patient suffering from a non-
Hodgkin's lymphoma [7] (Table 1). Out of these 9 cases
of bacteremia (including the present case), 8/9 (89%)
were male and 9/9 (100%) were older than 50 with a
severe underlying disease and/or an immunosuppression
leading to death in 66.7% of cases (6/9). In our patient, B.
pilosocoli blood isolate is likely to have originated in the
ischemic intestinal tract during cardiogenic shock since, in
such cases, blood isolates are closely related to fecal iso-
lates [14]. Translocation of bacteria or endotoxin from theAnnals of Clinical Microbiology and Antimicrobials 2008, 7:19 http://www.ann-clinmicrob.com/content/7/1/19
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intestinal tract commonly occurs in debilited patients as a
result of overgrowth of Gram-negative bacteria, impaired
host defenses, or injury to the gut mucosa resulting in
increased mucosal permeability [6].
Although spirochetemia remains very rare, incidence of B.
pilosicoli bacteremia is probably more common than clin-
ically appreciated since detection time in automated
growth detection systems often exceed 5 days under
anaerobic conditions [15]. In addition, subculture of B.
pilosicoli from blood culture media is also fastidious (gen-
erally from 3 to 5 days at 37°C) and phenotypic identifi-
cation to the species-level cannot be achieved by using
available commercial kits [2]. By contrast, the use of gen-
otypic identification by sequencing the 16S rRNA gene
allows clear identification to the species-level. Therefore,
the use of PCR assays using specific primers for the 16S
rRNA gene to directly identify the spirochetes recovered in
blood should be strongly recommended.
Even if the diagnosis is often delayed like here, preferred
treatment of B. pilosicoli infections remains metronida-
zole. Indeed, all isolates of B. pilosicoli recovered from
humans (n = 123) were susceptible to metronidazole
[16]. Although β-lactam antibiotics are spirocheticidal,
our B. pilosicoli strain was resistant to penicillins due to
production of a β-lactamase. A novel class D β-lactamase
(OXA-63), recently identified in the chromosome of B.
pilosicoli  BM4442, may explain this phenotype [17].
Unfortunately, prevalence of blaOXA-63 gene has not been
studied; however, an in vitro antimicrobial susceptibility
survey on 139 B. pilosocoli clinical isolates showed a
54.7% susceptibility rate to amoxicillin, suggesting that
resistance to penicillins is common [16]. As previously
reported, our strain was also resistant to erythromycin,
but susceptible to third-generation cephalosporins, car-
bapenems, tetracyclin and chloramphenicol, [16]. The
resistance to macrolides in B. pilosicoli is due to point
mutations in positions 2058 and 2059 of the 23S rRNA
gene [18].
Conclusion
Our report confirms that B. pilosicoli may cause bacteremia
in immunocompromised and/or critically ill patients. The
contribution of the spirochetemia to the lethal outcome
of our patient remains unclear, since he was debilitated
with an underlying poorly controlled cardiogenic shock,
and received effective therapy. However, rapid and accu-
rate diagnosis methods (e.g. PCR assays) should be
employed to identify the etiologic microorganism and
help adapt antibiotic therapy for such infections.
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